Last updated on April 2018

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Brief description of study

This multiple-center, 3-Cohort, single-blind dose escalation (Cohort 1), randomized, double-blind (Cohort 2), and open-label multiple dose extension (Cohort 3C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.

Clinical Study Identifier: NCT02705755

Contact Investigators or Research Sites near you

Start Over

Omid Omidvar, MD

Collaborative Neuroscience Network, LLC.
Long Beach, CA United States
  Connect »

Aaron Ellenbogen, D.O.

Quest Research Institute
Farmington Hills, MI United States
  Connect »

Michael Hassman, M.D.

Hassman Research Institute
Berlin, NJ United States
  Connect »

Horacio Kaufmann, MD

NYU Langone Medical Center
New York, NY United States
  Connect »

Italo Biaggioni, MD

Vanderbilt University Medical Center
Nashville, TN United States
  Connect »

Meredith Bryarly, MD

University of Texas Southwestern Medical Center
Dallas, TX United States
  Connect »